Ilunocitinib

Ilunocitinib, sold under the brand name Zenrelia, is a veterinary medication used for the treatment of pruritus (itching) in dogs.^[1][3] It is a non-selective janus kinase inhibitor.^[3]

Ilunocitinib

Clinical data
Trade names	Zenrelia
Other names	LY-3411067
License data	US DailyMed: Ilunocitinib
Routes of administration	By mouth
ATC code	None
Legal status
Legal status	CA: ℞-only[1] US: ℞-only[2][3]
Identifiers
CAS Number	1187594-14-4
PubChem CID	44231134
IUPHAR/BPS	11670
ChemSpider	115006748
UNII	N3TB5AH8B9
ChEMBL	ChEMBL4802241
Chemical and physical data
Formula	C17H17N7O2S
Molar mass	383.43 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CC1S(=O)(=O)N2CC(C2)(CC#N)N3C=C(C=N3)C4=C5C=CNC5=NC=N4
InChI InChI=InChI=1S/C17H17N7O2S/c18-5-4-17(9-23(10-17)27(25,26)13-1-2-13)24-8-12(7-22-24)15-14-3-6-19-16(14)21-11-20-15/h3,6-8,11,13H,1-2,4,9-10H2,(H,19,20,21) Key:RVOUEXFKIYNODQ-UHFFFAOYSA-N

Ilunocitinib was approved for medical use in the United States in September 2024,^[4] and in Canada in December 2024.^[1]

Medical uses

Ilunocitinib is indicated for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least twelve months of age.^[1][3][5]

Contraindications

It is not safe to administer vaccines to dogs that are concurrently receiving ilunocitinib.^[5]

Society and culture

Legal status

Ilunocitinib was approved for medical use in the United States in September 2024,^[6] and in Canada in December 2024.^[1]

In June 2025, the Committee for Veterinary Medicinal Products of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the veterinary medicinal product Zenrelia, film-coated tablets, intended for dogs.^[7] The applicant for this veterinary medicinal product is Elanco GmbH.^[7]

Names

Ilunocitinib is the international nonproprietary name.^[8]

Ilunocitinib is sold under the brand name Zenrelia.^[1][3]